Rapid Fire 7
Session Details
Moderator
Reshma L Mahtani, Baptist Health Wertheim Cancer Institute, Miami, FL
Moderator
Joyce O'Shaughnessy
Presentation numberRF7-1
Efficacy and Safety of a 6-Month Pre‑mixed Depot formulation, Leuprorelin Mesylate Injection (6M) with Tamoxifen in Premenopausal HR+ Breast Cancer: A Phase III, Randomized, Open-Label, Non-Inferiority Study in China
Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China
Presentation numberRF7-2
I-SPY 2 Endocrine Optimization Pilot (EOP): elagolix vs GnRH agonist as ovarian function suppression (OFS) in premenopausal patients receiving neoadjuvant (Z)-endoxifen for estrogen receptor positive (ER+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC)
Annabelle Duflock, University of California, San Francisco, San Francisco, CA
Presentation numberRF7-3
A randomised non-comparative phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES); EORTC-1745-ETF-BCG
Hans Wildiers, university hospitals leuven, leuven, Belgium
Presentation numberRF7-4
Afuresertib and fulvestrant for PIK3CA/AKT1/PTEN-altered, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III part of LAE205INT3101 trial
Pin Zhang, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Presentation numberRF7-5
Updated Efficacy Results From LEONARDA-2: A Phase III, Randomized, Placebo-Controlled Trial of Lerociclib Plus Letrozole as First-Line Therapy for HR+/HER2- Advanced Breast Cancer
Xichun Hu, Fudan University Cancer Center, Shanghai, China